Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Ruggiero

Showing results (21-30 of 134) with videos related to

Pageof 14
Sort By:
Pediatric Health, Medicine and Therapeutics|November 29, 2023
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on BiologicsAngelo Ruggiero, Antonio Portarapillo, Matteo Megna, et al.
Clinical and Experimental Dermatology|September 2, 2022
Comment on 'Morphoea following COVID-19 vaccination'Fabrizio Martora, Teresa Battista, Angelo Ruggiero, et al.
Medical Hypotheses|June 4, 2020
May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?Claudio Marasca, Angelo Ruggiero, Maddalena Napolitano, et al.
Clinical, Cosmetic and Investigational Dermatology|August 23, 2022
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World EvidenceAngelo Ruggiero, Vincenzo Picone, Fabrizio Martora, et al.
Clinical and Experimental Dermatology|January 20, 2023
A unilateral slow-growing yellow nodule of the glans penisAngelo Ruggiero, Claudio Marasca, Gabriella Fabbrocini, et al.
Current Drug Safety|March 8, 2022
A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient Treated with GuselkumabMatteo Megna, Gabriella Fabbrocini, Lucia Gallo, et al.
Clinical and Experimental Dermatology|April 25, 2023
Comment on 'Associations between hidradenitis suppurativa and dermatological conditions in adults: a national cross-sectional study'Fabrizio Martora, Angelo Ruggiero, Teresa Battista, et al.
Expert Opinion on Drug Safety|December 17, 2022
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledgeAngelo Ruggiero, Elisa Camela, Luca Potestio, et al.
Immunologic Research|January 4, 2023
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials dataAngelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, et al.
International Journal of Dermatology|August 7, 2022
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et alMatteo Megna, Elisa Camela, Angelo Ruggiero, et al.
Pageof 14

Showing results (21-30 of 134) with videos related to

Sort By:
Pageof 14
Pediatric Health, Medicine and Therapeutics|November 29, 2023
Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on BiologicsAngelo Ruggiero, Antonio Portarapillo, Matteo Megna, et al.
Clinical and Experimental Dermatology|September 2, 2022
Comment on 'Morphoea following COVID-19 vaccination'Fabrizio Martora, Teresa Battista, Angelo Ruggiero, et al.
Medical Hypotheses|June 4, 2020
May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?Claudio Marasca, Angelo Ruggiero, Maddalena Napolitano, et al.
Clinical, Cosmetic and Investigational Dermatology|August 23, 2022
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World EvidenceAngelo Ruggiero, Vincenzo Picone, Fabrizio Martora, et al.
Clinical and Experimental Dermatology|January 20, 2023
A unilateral slow-growing yellow nodule of the glans penisAngelo Ruggiero, Claudio Marasca, Gabriella Fabbrocini, et al.
Current Drug Safety|March 8, 2022
A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient Treated with GuselkumabMatteo Megna, Gabriella Fabbrocini, Lucia Gallo, et al.
Clinical and Experimental Dermatology|April 25, 2023
Comment on 'Associations between hidradenitis suppurativa and dermatological conditions in adults: a national cross-sectional study'Fabrizio Martora, Angelo Ruggiero, Teresa Battista, et al.
Expert Opinion on Drug Safety|December 17, 2022
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledgeAngelo Ruggiero, Elisa Camela, Luca Potestio, et al.
Immunologic Research|January 4, 2023
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials dataAngelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, et al.
International Journal of Dermatology|August 7, 2022
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et alMatteo Megna, Elisa Camela, Angelo Ruggiero, et al.
Pageof 14